Marengo Therapeutics to Present at SITC 2025
Marengo Therapeutics, Inc., a clinical-stage biotechnology company, will present a late-breaking oral abstract at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting.
The presentation will highlight initial Phase 2 monotherapy results from the STARt-001 trial, evaluating Invikafusp alfa in tissue-agnostic, tumor mutational burden-high (TMB-H) advanced cancers.
- Event: SITC 2025 Annual Meeting
- Dates: November 5-9, 2025
- Location: National Harbor, Maryland
No direct quotes available in the text.
Author's summary: Marengo Therapeutics presents Invikafusp alfa results.
More News
- Stephen A. Smith Questions Why Chris Grier Got Fired Before Mike McDaniel After Dolphins' Embarrassing Loss
- A.J. Brown, other injured Eagles have a crucial 15 days to recover thanks to bye week
- Pras Michel Must Forfeit $64 Million After Criminal Convictions in Foreign Influence Case
- Bose headphones and earbuds return to all-time lows for Black Friday
- No Giannis, No Problem — Bucks Take Down Warriors as Antetokounmpo Steals the Show in Minion Costume
- The unexpected reaction of Tyreek Hill after the firing of Dolphins general manager Chris Grier
- Why Ryan Rollins loved Draymond Green coming for him after Stephen Curry incident